Abstract
We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 936-942 |
| Number of pages | 7 |
| Journal | Digestive and Liver Disease |
| Volume | 46 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Hepatology
- Gastroenterology
Keywords
- Boceprevir
- Cost-effectiveness
- Peg-interferon
Fingerprint
Dive into the research topics of 'Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver